The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.
ESMO GI Data: Agenus Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Agenus , a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab in combination with. | May 3, 2023